Richard A. Miller M.D., President and CEO at Corvus Pharmaceuticals, Inc. (CRVS), bought 6,932 shares at $12.05 ($83K) on 2026-05-18, disclosed to the SEC on 2026-05-20.
CEO Richard A. Miller purchased 5,000 shares for $60,250, marking the largest insider purchase in the company's history. This significant buy by the CEO comes as the stock has dropped over 20% in the last month, potentially signaling confidence in the current valuation.
The stock is currently trading at $12.17, down 23.17% over the past five days and 30.58% over the last 90 days, despite a massive 230.71% gain over the last year. The current price sits 54.84% below the 52-week high of $26.95.
Catalysts include a $18 million bet from Boxer Capital on May 17 and the company's focus on a Phase II Atopic Dermatitis trial for soquelitinib in 2026. Additionally, the largest insider purchase in the company's history by CEO Richard Miller serves as a bullish signal.
Risks include a shift back to losses, with Q1 2026 showing a net loss of $13.69 million compared to net income a year prior, alongside a new $46.16 million shelf offering. Furthermore, the stock carries a high short interest of 24.85% of the float.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.01 | 1,932 | $23K | 27.8% |
| 2 | $12.05 | 5,000 | $60K | 72.2% |
| Total | $12.04 avg | 6,932 | $83K | 100% |
| Filing → |
| CRVS | BUY | 2022-09-28 | $19K | — | Filing → |
| CRVS | BUY | 2022-09-20 | $16K | — | Filing → |
| CRVS | BUY | 2022-06-28 | $10K | — | Filing → |